Symbols / HCM Stock $14.00 +0.94% HUTCHMED (China) Limited

Healthcare • Drug Manufacturers - Specialty & Generic • Hong Kong • NMS
HCM (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Mr. Chig Fung Cheng BEc, CA
Exch · Country NMS · Hong Kong
Market Cap 2.41B
Enterprise Value 10.78B
Income 456.91M
Sales 548.51M
FCF (ttm) -54.01M
Book/sh 7.20
Cash/sh 1.59
Employees 1,796
Insider 10d —
IPO Mar 16, 2016
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 5.28
Forward P/E 26.95
PEG —
P/S 4.39
P/B 1.94
P/C —
EV/EBITDA -416.94
EV/Sales 19.65
Quick Ratio 4.81
Current Ratio 4.96
Debt/Eq 7.82
LT Debt/Eq —
EPS (ttm) 2.65
EPS next Y 0.52
EPS Growth -98.10%
Revenue Growth -16.50%
EPS Gr Q/Q -83.60%
Rev Gr Q/Q —
Earnings (next) 2026-03-05
Earnings (prior) 2026-03-05
ROA -1.62%
ROE 45.25%
ROIC —
Gross Margin 11.64%
Oper. Margin -13.16%
Profit Margin 83.30%
Shs Outstand 171.95M
Shs Float 508.43M
Insider Own 0.01%
Instit Own 3.07%
Short Float 0.30%
Short Ratio 8.94
Short Interest 306.83K
52W High 19.50
vs 52W High -28.21%
52W Low 12.98
vs 52W Low 7.86%
Beta 0.45
Impl. Vol. 1.90%
Rel Volume 0.68
Avg Volume 29.12K
Volume 19.72K
Target (mean) $22.85
Tgt Median $21.28
Tgt Low $13.75
Tgt High $40.40
# Analysts 15
Recom None
Prev Close $13.87
Price $14.00
Change 0.94%
About

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$22.85
Mean price target
2. Current target
$14.00
Latest analyst target
3. DCF / Fair value
$-5.65
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$14.00
Low
$13.75
High
$40.40
Mean
$22.85

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-10 main B of A Securities Buy → Buy $20
2025-09-22 down Morgan Stanley Equal-Weight → Underweight $14
2025-07-22 main B of A Securities Buy → Buy $28
2024-08-01 main Goldman Sachs Neutral → Neutral $19
2023-11-24 up Deutsche Bank Hold → Buy $22
2023-11-10 main Goldman Sachs Neutral → Neutral $17
2023-09-05 reit Cantor Fitzgerald Overweight → Overweight $50
2023-07-24 reit Cantor Fitzgerald Overweight → Overweight $50
2022-08-09 main Goldman Sachs — → Neutral $16
2022-08-02 main Goldman Sachs — → Neutral $14
2021-09-22 down Goldman Sachs Buy → Neutral $46
2021-08-03 init Jefferies — → Buy $52
2020-03-13 init Cantor Fitzgerald — → Overweight —
2020-02-20 init Goldman Sachs — → Buy $38
2019-11-19 init CLSA — → Buy —
2019-03-04 init Deutsche Bank — → Buy —
2017-10-17 main Canaccord Genuity — → Buy $38
2016-04-11 init Stifel — → Buy —
2016-04-11 init Canaccord Genuity — → Buy $20
2016-04-11 init B of A Securities — → Buy —
News
RSS: Latest HCM news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
548.51
-12.96%
630.20
-24.80%
838.00
+96.52%
426.41
Operating Revenue
548.51
-12.96%
630.20
-24.80%
838.00
+96.52%
426.41
Cost Of Revenue
336.35
-3.59%
348.88
-9.25%
384.45
+23.58%
311.10
Reconciled Cost Of Revenue
336.35
-3.59%
348.88
-9.25%
384.45
+23.58%
311.10
Gross Profit
212.16
-24.58%
281.32
-37.97%
453.55
+293.35%
115.31
Operating Expense
247.86
-23.01%
321.93
-25.49%
432.04
-17.16%
521.57
Research And Development
148.29
-30.09%
212.11
-29.77%
302.00
-21.94%
386.89
Selling General And Administration
103.03
-8.75%
112.91
-15.22%
133.18
-2.15%
136.11
Selling And Marketing Expense
36.31
-25.32%
48.62
-8.94%
53.39
+21.53%
43.93
General And Administrative Expense
66.72
+3.77%
64.30
-19.41%
79.78
-13.44%
92.17
Other Operating Expenses
5.51
—
—
—
Total Expenses
584.21
-12.91%
670.81
-17.84%
816.49
-1.94%
832.67
Operating Income
-35.70
+12.09%
-40.61
-288.80%
21.51
+105.29%
-406.26
EBITDA
514.86
+3549.96%
14.11
-79.03%
67.27
+116.77%
-401.11
Normalized EBITDA
36.02
+90.48%
18.91
-74.11%
73.04
+118.32%
-398.65
Reconciled Depreciation
13.31
+7.84%
12.34
+50.37%
8.21
-5.27%
8.66
EBIT
501.56
+28316.77%
1.76
-97.01%
59.07
+114.41%
-409.77
Total Unusual Items
478.84
+10067.61%
-4.80
+16.68%
-5.77
-135.15%
-2.45
Total Unusual Items Excluding Goodwill
478.84
+10067.61%
-4.80
+16.68%
-5.77
-135.15%
-2.45
Special Income Charges
476.81
+10025.21%
-4.80
+16.68%
-5.77
0.00
Other Special Charges
-476.90
—
—
—
Impairment Of Capital Assets
0.09
-98.15%
4.80
-16.68%
5.77
0.00
Net Income
456.91
+1111.03%
37.73
-62.56%
100.78
+127.93%
-360.83
Pretax Income
498.69
+45148.87%
-1.11
-101.90%
58.31
+114.21%
-410.42
Net Non Operating Interest Income Expense
47.01
+26.35%
37.21
+5.15%
35.39
+295.51%
8.95
Interest Expense Non Operating
2.87
-0.24%
2.87
+278.39%
0.76
+16.41%
0.65
Net Interest Income
47.01
+26.35%
37.21
+5.15%
35.39
+295.51%
8.95
Interest Expense
2.87
-0.24%
2.87
+278.39%
0.76
+16.41%
0.65
Interest Income Non Operating
49.88
+24.44%
40.08
+10.89%
36.15
+276.55%
9.60
Interest Income
49.88
+24.44%
40.08
+10.89%
36.15
+276.55%
9.60
Other Non Operating Income Expenses
3.54
+73.47%
2.04
+237.58%
-1.48
+70.08%
-4.95
Tax Provision
63.61
+784.45%
7.19
+59.50%
4.51
+1693.29%
-0.28
Tax Rate For Calcs
0.00
-48.98%
0.00
+65.56%
0.00
+4.86%
0.00
Tax Effect Of Unusual Items
61.08
+5185.63%
-1.20
-37.94%
-0.87
-146.59%
-0.35
Net Income Including Noncontrolling Interests
457.73
+1099.19%
38.17
-62.24%
101.09
+128.05%
-360.39
Net Income From Continuing Operation Net Minority Interest
456.91
+1111.03%
37.73
-62.56%
100.78
+127.93%
-360.83
Net Income From Continuing And Discontinued Operation
456.91
+1111.03%
37.73
-62.56%
100.78
+127.93%
-360.83
Net Income Continuous Operations
457.73
+1099.19%
38.17
-62.24%
101.09
+128.05%
-360.39
Minority Interests
-0.82
-86.62%
-0.44
-40.45%
-0.31
+30.07%
-0.45
Normalized Income
39.14
-5.30%
41.33
-60.89%
105.68
+129.46%
-358.74
Net Income Common Stockholders
456.91
+1111.03%
37.73
-62.56%
100.78
+127.93%
-360.83
Otherunder Preferred Stock Dividend
0.00
0.00
0.00
0.00
Diluted EPS
2.65
+1225.00%
0.20
-66.67%
0.60
+127.91%
-2.15
Basic EPS
2.65
+1225.00%
0.20
-66.67%
0.60
+127.91%
-2.15
Basic Average Shares
171.66
+0.34%
171.07
+0.67%
169.93
+0.30%
169.43
Diluted Average Shares
174.58
+0.01%
174.57
+0.42%
173.84
+2.60%
169.43
Diluted NI Availto Com Stockholders
456.91
+1111.03%
37.73
-62.56%
100.78
+127.93%
-360.83
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
1,753.10
+37.58%
1,274.20
-0.44%
1,279.77
+24.32%
1,029.44
Current Assets
1,567.34
+46.95%
1,066.56
-2.76%
1,096.84
+30.59%
839.89
Cash Cash Equivalents And Short Term Investments
1,367.28
+63.53%
836.11
-5.67%
886.34
+40.47%
631.00
Cash And Cash Equivalents
71.33
-53.67%
153.96
-45.71%
283.59
-9.48%
313.28
Cash Equivalents
14.01
-79.83%
69.48
-54.77%
153.62
+13.83%
134.95
Cash Financial
57.32
-32.15%
84.48
-35.00%
129.97
-27.12%
178.33
Other Short Term Investments
1,295.94
+89.98%
682.15
+13.17%
602.75
+89.71%
317.72
Accounts Receivable
126.75
-18.51%
155.54
+33.06%
116.89
+19.29%
97.99
Gross Accounts Receivable
126.75
-18.54%
155.61
+32.92%
117.06
+19.40%
98.05
Allowance For Doubtful Accounts Receivable
-0.00
+95.71%
-0.07
+59.06%
-0.17
-185.00%
-0.06
Other Receivables
18.28
+49.80%
12.21
-63.03%
33.01
+13.13%
29.18
Taxes Receivable
4.57
+38.52%
3.30
+52.22%
2.17
+45.27%
1.49
Inventory
41.13
-18.39%
50.40
+0.28%
50.26
-11.35%
56.69
Raw Materials
22.45
-7.79%
24.35
-9.09%
26.78
-2.22%
27.39
Finished Goods
18.68
-28.30%
26.05
+10.98%
23.47
-19.88%
29.30
Prepaid Assets
9.34
+3.69%
9.01
+10.18%
8.17
-65.28%
23.54
Total Non Current Assets
185.75
-10.54%
207.64
+13.51%
182.93
-3.49%
189.56
Net PPE
97.65
+0.68%
97.00
-7.09%
104.39
+23.29%
84.67
Gross PPE
171.16
+9.50%
156.31
+3.54%
150.96
+24.21%
121.53
Accumulated Depreciation
-73.51
-23.93%
-59.32
-27.37%
-46.57
-26.33%
-36.86
Properties
0.00
0.00
0.00
0.00
Land And Improvements
—
—
—
—
Buildings And Improvements
91.04
+12.84%
80.68
+2.04%
79.07
+186.59%
27.59
Machinery Furniture Equipment
78.75
+15.73%
68.05
+7.50%
63.30
+61.52%
39.19
Construction In Progress
1.08
-85.09%
7.27
-13.69%
8.42
-84.56%
54.55
Other Properties
0.28
-10.09%
0.32
+86.47%
0.17
-15.42%
0.20
Goodwill And Other Intangible Assets
3.11
+4.08%
2.99
—
—
Goodwill
3.11
+4.08%
2.99
—
—
Other Intangible Assets
—
—
—
—
Long Term Equity Investment
10.87
-86.03%
77.77
+60.63%
48.41
-34.38%
73.78
Non Current Deferred Taxes Assets
12.65
+1.66%
12.45
-19.46%
15.46
+0.59%
15.37
Non Current Prepaid Assets
—
—
—
—
Other Non Current Assets
20.09
+61.47%
12.44
-15.21%
14.68
-6.80%
15.74
Total Liabilities Net Minority Interest
501.83
-0.10%
502.34
-6.35%
536.39
+36.63%
392.57
Current Liabilities
315.77
-16.14%
376.56
-6.57%
403.03
+13.88%
353.90
Payables
64.32
+6.87%
60.19
+13.33%
53.11
-41.09%
90.15
Accounts Payable
45.53
+7.08%
42.52
+17.05%
36.33
-48.92%
71.11
Other Payable
16.70
+3.64%
16.12
+13.50%
14.20
-20.78%
17.93
Total Tax Payable
2.08
+34.47%
1.55
-39.96%
2.58
+132.01%
1.11
Current Debt And Capital Lease Obligation
27.85
+5.91%
26.30
-25.04%
35.08
+846.12%
3.71
Current Debt
24.97
+6.84%
23.37
-24.98%
31.16
0.00
Current Capital Lease Obligation
2.88
-1.50%
2.92
-25.52%
3.93
+5.91%
3.71
Other Current Liabilities
0.25
-95.59%
5.66
+198.68%
1.90
-88.88%
17.05
Total Non Current Liabilities Net Minority Interest
186.06
+47.92%
125.78
-5.68%
133.36
+244.85%
38.67
Long Term Debt And Capital Lease Obligation
70.04
+10.26%
63.52
+24.44%
51.05
+119.09%
23.30
Long Term Debt
68.19
+14.73%
59.43
+23.34%
48.19
+166.18%
18.10
Long Term Capital Lease Obligation
1.85
-54.71%
4.09
+42.97%
2.86
-44.96%
5.20
Long Term Provisions
79.96
—
—
—
Tradeand Other Payables Non Current
6.33
-4.41%
6.62
—
—
Non Current Deferred Revenue
20.13
-58.43%
48.43
-30.29%
69.48
+36468.42%
0.19
Non Current Deferred Taxes Liabilities
0.26
-91.47%
2.99
+101.48%
1.48
-45.24%
2.71
Other Non Current Liabilities
9.35
+121.62%
4.22
-62.82%
11.35
-9.03%
12.47
Stockholders Equity
1,237.93
+62.90%
759.93
+4.02%
730.54
+19.69%
610.37
Common Stock Equity
1,237.93
+62.90%
759.93
+4.02%
730.54
+19.69%
610.37
Capital Stock
87.23
+0.08%
87.16
+0.04%
87.13
+0.75%
86.48
Common Stock
87.23
+0.08%
87.16
+0.04%
87.13
+0.75%
86.48
Share Issued
872.33
+0.08%
871.60
+0.04%
871.26
+0.75%
864.78
Ordinary Shares Number
859.74
+0.57%
854.88
+0.15%
853.64
+1.00%
845.17
Treasury Shares Number
12.58
-24.73%
16.72
-5.08%
17.61
-10.15%
19.60
Additional Paid In Capital
1,533.87
+1.08%
1,517.53
-0.32%
1,522.45
+1.68%
1,497.27
Retained Earnings
-378.64
+54.55%
-833.17
+4.33%
-870.87
+10.36%
-971.48
Minority Interest
13.34
+11.84%
11.92
-7.18%
12.85
-51.53%
26.50
Total Equity Gross Minority Interest
1,251.26
+62.11%
771.85
+3.83%
743.39
+16.73%
636.87
Total Capitalization
1,306.12
+59.41%
819.36
+5.22%
778.73
+23.91%
628.47
Working Capital
1,251.57
+81.39%
689.99
-0.55%
693.81
+42.76%
485.99
Invested Capital
1,331.09
+57.95%
842.74
+4.06%
809.88
+28.87%
628.47
Total Debt
97.89
+8.99%
89.82
+4.28%
86.13
+218.91%
27.01
Net Debt
21.83
—
—
—
Capital Lease Obligations
4.73
-32.52%
7.01
+3.34%
6.79
-23.78%
8.90
Net Tangible Assets
1,234.81
+63.13%
756.94
+3.61%
730.54
+19.69%
610.37
Tangible Book Value
1,234.81
+63.13%
756.94
+3.61%
730.54
+19.69%
610.37
Available For Sale Securities
—
5.00
—
—
Current Deferred Taxes Liabilities
5.51
0.00
—
—
Financial Assets
—
—
—
—
Investmentin Financial Assets
0.00
-100.00%
5.00
0.00
—
Investments In Other Ventures Under Equity Method
—
—
0.00
-100.00%
0.32
Investmentsin Joint Venturesat Cost
—
77.77
+60.63%
48.41
-34.10%
73.46
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-64.66
-13109.46%
0.50
-99.77%
219.26
+181.63%
-268.60
Net Income From Continuing Operations
457.73
+1099.19%
38.17
-62.24%
101.09
+128.05%
-360.39
Depreciation
13.31
+7.84%
12.34
+50.37%
8.21
-5.27%
8.66
Depreciation And Amortization
13.31
+7.84%
12.34
+50.37%
8.21
-5.27%
8.66
Other Non Cash Items
1.57
+131.76%
-4.95
-234.05%
3.69
+34.79%
2.74
Stock Based Compensation
15.29
-29.23%
21.61
-40.96%
36.60
+19.66%
30.59
Provisionand Write Offof Assets
-0.29
-152.65%
0.55
-19.20%
0.68
+101.49%
0.34
Deferred Tax
1.20
-66.74%
3.60
+362.18%
0.78
+104.07%
-19.17
Gain Loss On Investment Securities
—
—
—
2.45
Net Foreign Currency Exchange Gain Loss
1.92
+4020.41%
-0.05
+96.89%
-1.57
-111.86%
13.27
Gain Loss On Sale Of PPE
-0.02
-310.00%
0.01
-88.37%
0.09
-22.52%
0.11
Change In Working Capital
-60.86
+2.10%
-62.17
-187.38%
71.15
+21.19%
58.70
Change In Receivables
24.22
+158.27%
-41.57
-218.54%
-13.05
-448.59%
-2.38
Change In Inventory
9.54
+1336.01%
-0.77
-118.67%
4.13
+119.49%
-21.21
Change In Payable
-45.83
-738.76%
7.17
+118.71%
-38.35
-146.45%
82.57
Change In Other Current Assets
-48.02
-75.44%
-27.37
-122.78%
120.17
+18560.56%
0.64
Change In Other Current Liabilities
-0.78
-306.67%
0.38
+121.32%
-1.76
-92.24%
-0.92
Investing Cash Flow
-29.41
+69.38%
-96.06
+67.01%
-291.14
-198.16%
296.59
Net PPE Purchase And Sale
-14.12
+15.22%
-16.66
+48.93%
-32.61
+11.05%
-36.66
Purchase Of PPE
-14.15
+21.11%
-17.93
+45.01%
-32.61
+11.05%
-36.66
Sale Of PPE
0.03
-97.81%
1.28
0.00
0.00
Capital Expenditure
-24.15
-34.66%
-17.93
+45.01%
-32.61
+11.05%
-36.66
Net Investment Purchase And Sale
-613.79
-672.99%
-79.41
+72.14%
-285.03
-190.07%
316.44
Purchase Of Investment
-2,742.21
-48.32%
-1,848.81
-13.57%
-1,627.88
-35.43%
-1,202.01
Sale Of Investment
2,128.42
+20.29%
1,769.40
+31.77%
1,342.85
-11.56%
1,518.45
Net Business Purchase And Sale
608.50
0.00
+100.00%
-2.99
-1022.84%
0.32
Purchase Of Business
0.00
0.00
+100.00%
-8.09
0.00
Gain Loss On Sale Of Business
-478.93
0.00
+100.00%
-0.14
0.00
Net Intangibles Purchase And Sale
-10.00
0.00
0.00
—
Purchase Of Intangibles
-10.00
0.00
0.00
—
Financing Cash Flow
7.84
+125.55%
-30.67
-163.02%
48.66
+158.79%
-82.76
Net Issuance Payments Of Debt
6.26
+11.61%
5.61
-90.91%
61.70
+772.90%
-9.17
Issuance Of Debt
30.90
-14.64%
36.20
-41.34%
61.70
+247.58%
17.75
Repayment Of Debt
-24.64
+19.46%
-30.59
0.00
+100.00%
-26.92
Long Term Debt Issuance
30.90
-14.64%
36.20
-41.34%
61.70
+247.58%
17.75
Long Term Debt Payments
-24.64
+19.46%
-30.59
0.00
+100.00%
-26.92
Net Long Term Debt Issuance
6.26
+11.61%
5.61
-90.91%
61.70
+772.90%
-9.17
Net Common Stock Issuance
1.58
+104.47%
-35.27
-786.95%
-3.98
+91.70%
-47.91
Common Stock Payments
0.00
+100.00%
-36.06
-297.57%
-9.07
+81.14%
-48.08
Repurchase Of Capital Stock
0.00
+100.00%
-36.06
-297.57%
-9.07
+81.14%
-48.08
Net Other Financing Charges
—
—
—
—
Changes In Cash
-86.23
+31.69%
-126.23
-443.67%
-23.22
+57.61%
-54.77
Effect Of Exchange Rate Changes
3.60
+205.94%
-3.40
+47.44%
-6.47
+31.81%
-9.49
Beginning Cash Position
153.96
-45.71%
283.59
-9.48%
313.28
-17.02%
377.54
End Cash Position
71.33
-53.67%
153.96
-45.71%
283.59
-9.48%
313.28
Free Cash Flow
-88.81
-409.32%
-17.44
-109.34%
186.65
+161.14%
-305.26
Common Stock Issuance
1.58
+99.75%
0.79
-84.49%
5.09
+2827.59%
0.17
Dividend Received CFO
6.99
-80.00%
34.94
-17.42%
42.31
-3.23%
43.72
Dividends Received CFI
0.00
0.00
-100.00%
29.50
+78.89%
16.49
Issuance Of Capital Stock
1.58
+99.75%
0.79
-84.49%
5.09
+2827.59%
0.17
Sale Of Business
608.50
0.00
-100.00%
5.10
+1475.00%
0.32
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category